Drug intelligence / Profile preview

Artelac Complete MDO

Development stage: Unknown
Lead developer: Dr. Gerhard Mann
Modality: Small Molecules
Administration: Ophthalmic

Overview

Artelac Complete MDO is a multi-dose, preservative-free ophthalmic solution developed by Dr. Gerhard Mann (a Bausch & Lomb company) for the treatment of moderate to severe dry eye disease. It is formulated as a triple-action lubricant that addresses all three layers of the natural tear film: the lipid layer (via a lipid component to reduce evaporation), the aqueous layer (via 0.24% hyaluronic acid and glycerin to bind moisture), and the mucin-like layer (via carbomer to retain water on the ocular surface). The product is delivered through a specialized multi-dose pump (MDO) system that ensures sterility for up to six months after opening without the need for preservatives.

Brand names: Artelac Complete MDOArtelac Complete
Other names: Artelac Complete MDO Eye Drops

Beyond the preview

Go deeper on Artelac Complete MDO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Artelac Complete MDO.

Explore the full profile